Cargando…

Safety and immunogenicity of a SARS-CoV-2 inactivated vaccine in patients with chronic hepatitis B virus infection

Detalles Bibliográficos
Autores principales:	Xiang, Tiandan, Liang, Boyun, Wang, Hua, Quan, Xufeng, He, Shengsong, Zhou, Helong, He, Yongwen, Yang, Dongliang, Wang, Baoju, Zheng, Xin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8591435/ https://www.ncbi.nlm.nih.gov/pubmed/34782756 http://dx.doi.org/10.1038/s41423-021-00795-5

Ejemplares similares

Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting
por: Li, Ziwei, et al.
Publicado: (2021)

Robust humoral and cellular immune responses in long-term convalescent COVID-19 individuals following one-dose SARS-CoV-2 inactivated vaccination
por: Liang, Boyun, et al.
Publicado: (2022)

SARS-CoV-2-specific T cell responses wane profoundly in convalescent individuals 10 months after primary infection
por: Li, Ziwei, et al.
Publicado: (2023)

Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine
por: Zeng, Guangting
Publicado: (2022)

Safety and immunogenicity of inactivated SARS-CoV-2 vaccines in people with gastrointestinal cancer
por: Li, Tong, et al.
Publicado: (2022)

Safety and immunogenicity of inactivated SARS-CoV-2 vaccines in people living with HIV
por: Ao, Ling, et al.
Publicado: (2022)

Imatinib is not a potent anti-SARS-CoV-2 drug
por: Zhao, Helong, et al.
Publicado: (2020)

Declining Levels of Neutralizing Antibodies Against SARS-CoV-2 in Convalescent COVID-19 Patients One Year Post Symptom Onset
por: Xiang, Tiandan, et al.
Publicado: (2021)

Inactivation of SARS-CoV-2 by gamma irradiation
por: Jain, Rajlaxmi, et al.
Publicado: (2021)

Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine: Preclinical Studies
por: Kandeil, Ahmed, et al.
Publicado: (2021)

Improvement of a SARS-CoV-2 vaccine by enhancing the conjugation efficiency of the immunogen to self-assembled nanoparticles
por: Zhang, Xiantao, et al.
Publicado: (2021)

Humoral responses in naive or SARS-CoV-2 experienced individuals vaccinated with an inactivated vaccine
por: Peng, Pai, et al.
Publicado: (2021)

Safety and Immunogenicity of Inactivated and Recombinant Protein SARS-CoV-2 Vaccines in Patients With Thyroid Cancer
por: Han, Yuling, et al.
Publicado: (2022)

Comparative immunogenicity of mRNA and inactivated vaccines against COVID-19
por: Lim, Wey Wen, et al.
Publicado: (2021)

Omicron SARS-CoV-2 Neutralization from Inactivated and ZF2001 Vaccines
por: Zhao, Xin, et al.
Publicado: (2022)

The humoral and cellular immune evasion of SARS-CoV-2 Omicron and sub-lineages
por: Xiang, Tiandan, et al.
Publicado: (2022)

Acceptance, safety and immunogenicity of a booster dose of inactivated SARS-CoV-2 vaccine in adults with tuberculosis
por: Zhan, Haoting, et al.
Publicado: (2023)

Cross-neutralization of SARS-CoV-2 Kappa and Delta variants by inactivated vaccine-elicited serum and monoclonal antibodies
por: Cheng, Lin, et al.
Publicado: (2021)

Safety and immunogenicity evaluation of inactivated whole-virus-SARS-COV-2 as emerging vaccine development in Egypt
por: Saleh, Amani A, et al.
Publicado: (2021)

Immunogenicity and Safety of Beta-Adjuvanted Recombinant Booster Vaccine
por: Launay, Odile, et al.
Publicado: (2022)

Immunogenicity and reactogenicity of inactivated SARS-CoV-2 vaccines in healthy adults
por: Wu, Yufei, et al.
Publicado: (2023)

Immunogenic properties of SARS-CoV-2 inactivated by ultraviolet light
por: Gracheva, A. V., et al.
Publicado: (2022)

Immunogenicity Evaluating of the Multivalent COVID-19 Inactivated Vaccine against the SARS-CoV-2 Variants
por: Zhang, Yuntao, et al.
Publicado: (2022)

SARS-CoV-2-specific T cell immunity to structural proteins in inactivated COVID-19 vaccine recipients
por: Deng, Yao, et al.
Publicado: (2021)

Disseminated herpes zoster following inactivated SARS-CoV-2 vaccine in a healthy old man
por: Zhang, Li-wen, et al.
Publicado: (2022)

Immunogenicity, safety, and protective efficacy of an inactivated SARS-associated coronavirus vaccine in rhesus monkeys
por: Zhou, Jun, et al.
Publicado: (2005)

Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients
por: Liu, Jing, et al.
Publicado: (2020)

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in inadvertently vaccinated healthy children
por: Fernandes, Eder Gatti, et al.
Publicado: (2021)

CoronaVac: A review of efficacy, safety, and immunogenicity of the inactivated vaccine against SARS-CoV-2
por: Jin, Lairun, et al.
Publicado: (2022)

Immunogenicity and safety of inactivated SARS-CoV-2 vaccine in haemodialysis patients: a prospective cohort study
por: Puspitasari, Metalia, et al.
Publicado: (2023)

Immunogenicity of SARS inactivated vaccine in BALB/c mice
por: Xiong, Sheng, et al.
Publicado: (2004)

A protein subunit vaccine booster following two doses of inactivated SARS-CoV-2 vaccine provides high neutralisation of SARS-CoV-2 and its variants in mice
por: Zhang, Rong, et al.
Publicado: (2022)

Evaluation of Immunogenicity of an Inactivated SARS-CoV-2 Vaccine Prototype in vitro
por: Hancharou, Andrei, et al.
Publicado: (2022)

Immunogenicity of anti-SARS-CoV-2 Comirnaty vaccine in patients with lymphomas and myeloma who underwent autologous stem cell transplantation
por: Salvini, Marco, et al.
Publicado: (2021)

Immunogenicity of a Fourth Homologous Dose of NVX-CoV2373
por: Alves, Katia, et al.
Publicado: (2023)

Severe acute hepatitis in children: investigate SARS-CoV-2 superantigens
por: Brodin, Petter, et al.
Publicado: (2022)

Safety and immunogenicity of the third (booster) dose of inactivated and recombinant protein SARS-CoV-2 vaccine for patients with endocrine-related cancer
por: Han, Shanshan, et al.
Publicado: (2023)

The safety and immunogenicity of inactivated COVID-19 vaccine in old pulmonary tuberculosis patients
por: Yang, Lei, et al.
Publicado: (2023)

Fingolimod impairs inactivated vaccine (CoronaVac)-induced antibody response to SARS-CoV-2 spike protein in persons with multiple sclerosis
por: Türkoğlu, Recai, et al.
Publicado: (2022)

A three-dose inactivated SARS-CoV-2 vaccine is sufficient to elicit humoral immune responses in people living with HIV-1
por: Yu, Haisheng, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_l1mvmqbncvvh8i7fd0n9c7tkd5